about
Beta adrenergic antagonists for hospitalized burned patientsCardiovascular Dysfunction Following Burn Injury: What We Have Learned from Rat and Mouse ModelsThe Role of CHI3L1 (Chitinase-3-Like-1) in the Pathogenesis of Infections in Burns in a Mouse ModelOxandrolone Coadministration Does Not Alter Plasma Propranolol Concentrations in Severely Burned Pediatric Patients.Identification of selected in vitro generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes.Nephrilin peptide modulates a neuroimmune stress response in rodent models of burn trauma and sepsis.Burns: Pathophysiology of Systemic Complications and Current Management.Nutrition and anabolic pharmacotherapies in the care of burn patients.Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysisAdipose tissue: between the extremes.Propranolol Reduces Cardiac Index But does not Adversely Affect Peripheral Perfusion in Severely Burned Children.A randomized controlled trial to compare the effects of liquid versus powdered recombinant human growth hormone in treating patients with severe burns.Antimicrobial Brazilian Propolis (EPP-AF) Containing Biocellulose Membranes as Promising Biomaterial for Skin Wound HealingUse of Ubp1 protease analog to produce recombinant human growth hormone in Escherichia coli.Traditional Herbal Remedies for Burn Wound Healing in Canon of Avicenna.Cardiorespiratory Capacity and Strength Remain Attenuated in Children with Severe Burn Injuries at Over 3 Years Postburn.
P2860
Q24187666-DC63C115-8D70-4B52-87F4-84256CDF10C0Q26771250-F4221DAA-B253-4436-AE43-F6D6CB91677DQ27313397-1C23525E-7521-43FB-91D0-2A95163522B3Q30490969-EF867CA4-75B1-430C-9F47-998CB7A7CC14Q33468414-AB069EA0-FA42-4749-BE7B-A556290A019AQ37310277-C3306103-DB56-48AD-8E24-04D31167933EQ37558018-1F190A9C-E04D-4174-B9E5-24EEC6D70A90Q38326632-8308DCED-8CE2-466C-86B6-A63CFA26F12CQ38749920-52411044-07BC-44F8-B77C-8CA1243526F4Q39379288-2391C7C9-8901-41BF-A94E-224A9FB91E0EQ39630013-F919505F-0DC3-4C1E-A44F-AD98463CE5E0Q40478600-82CB82B3-3C83-41D6-B3B9-B9C4D611D369Q42100648-83A4B71C-FA46-43A9-B08F-2643EB3A8E71Q42114570-5FD617E7-BF9A-400B-9BBD-27E6D11E21FBQ45948921-C20263B8-D6E6-4FA0-BD45-87E6462AE6F8Q47779074-B872E37D-B0A5-40F7-A349-52236FA330AE
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Burns: an update on current pharmacotherapy
@ast
Burns: an update on current pharmacotherapy
@en
Burns: an update on current pharmacotherapy
@nl
type
label
Burns: an update on current pharmacotherapy
@ast
Burns: an update on current pharmacotherapy
@en
Burns: an update on current pharmacotherapy
@nl
prefLabel
Burns: an update on current pharmacotherapy
@ast
Burns: an update on current pharmacotherapy
@en
Burns: an update on current pharmacotherapy
@nl
P2093
P2860
P3181
P1476
Burns: an update on current pharmacotherapy
@en
P2093
Celeste C Finnerty
David N Herndon
Ravi S Radhakrishnan
Yesenia Rojas
P2860
P304
P3181
P356
10.1517/14656566.2012.738195
P407
P577
2012-12-01T00:00:00Z